C
C. van de Ven
Researcher at Columbia University
Publications - 29
Citations - 611
C. van de Ven is an academic researcher from Columbia University. The author has contributed to research in topics: Transplantation & Stem cell. The author has an hindex of 11, co-authored 27 publications receiving 560 citations. Previous affiliations of C. van de Ven include Boston Children's Hospital & New York Medical College.
Papers
More filters
Journal ArticleDOI
Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production
TL;DR: The results suggest that there may be differential mechanisms regulating endogenous TPO, IL-11, and IL-6 levels during acute thrombocytopenia and suggest that the absolute number of circulating PLTs may not always be the sole regulator of endogenous T PO levels.
Journal ArticleDOI
A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients.
G. Del Toro,P. Satwani,Lauren Harrison,Y.-K. Cheung,M Brigid Bradley,D. George,D. Yamashiro,James Garvin,Donna Skerrett,Olga Bessmertny,K. Wolownik,C. Wischhover,C. van de Ven,Mitchell S. Cairo +13 more
TL;DR: Reduced intensity allogeneic stem cell transplantation in children is feasible and tolerable (⩽25% GF) and results in ⩽85% of recipients initially achieving ⩾50% donor chimerism.
Journal ArticleDOI
RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia
Isabel S. Jerchel,Alex Q. Hoogkamer,Ingrid M. Ariës,Elisabeth M.P. Steeghs,Judith M. Boer,Nicolle Besselink,Aurélie Boeree,C. van de Ven,H A de Groot-Kruseman,V de Haas,Martin A. Horstmann,G Escherich,Christian M. Zwaan,Edwin Cuppen,Marco J. Koudijs,Rob Pieters,M L den Boer +16 more
TL;DR: It is concluded that RAS pathway mutations are frequent, and that clonal, but not subclonal, mutations are associated with unfavorable risk parameters in newly diagnosed pediatric BCP-ALL and may designate patients eligible for MEK inhibitor treatment.
Journal ArticleDOI
Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases
M.B. Bradley,Prakash Satwani,L. Baldinger,Erin Morris,C. van de Ven,G. Del Toro,James Garvin,Diane George,Monica Bhatia,E. Roman,L.A. Baxter-Lowe,Joseph E. Schwartz,E. Qualter,R. Hawks,K. Wolownik,S. Foley,O. Militano,J. Leclere,Y.-K. Cheung,Mitchell S. Cairo +19 more
TL;DR: RI-UCBT may result in graft failure in specific high-risk chemo-naïve patients, but in more heavily pretreated pediatric and adolescent recipients results in rapid engraftment and may be associated with decreased severe GVHD and TRM.
Unrelated donor transplants Outcomes of unrelated cord blood transplantation in pediatric recipients
Jan Styczyński,Y.-K. Cheung,James Garvin,G.B. Billote,Donna Skerrett,K. Wolownik,C. Wischhover,R. Hawks,M.B. Bradley,G. Del Toro,D. George,Darrell J. Yamashiro,C. van de Ven +12 more
TL;DR: It is suggested that CD34/kg cell dose and non-TBI-ablative conditioning may be important variables influencing OS following UCBT in pediatric recipients, and the small number of patients should be viewed cautiously.